대웅제약
Not investment advice · For research purposes only; not a solicitation or an offer of any financial product. Past statistics do not indicate future outcomes. Facts from filings and public sources; not investment advice. No valuation estimate, direction or trading levels are provided.
① Fact table
Values as filed · consolidated / separate basis per year · no interpretation
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | Unit |
|---|---|---|---|---|---|---|
| 매출액 | 1,152,975,698,170 | 1,280,091,851,013 | 1,375,328,744,877 | 1,422,683,296,380 | 1,570,891,005,329 | KRW |
| 영업이익 | 88,902,176,601 | 95,797,148,532 | 122,591,949,287 | 147,942,198,476 | 196,782,415,375 | KRW |
| 당기순이익 | 24,661,003,500 | 42,239,518,343 | 121,738,683,176 | 24,734,510,693 | 195,855,574,637 | KRW |
| 자본총계 | 573,566,551,872 | 608,017,372,164 | 767,303,245,365 | 794,574,152,015 | 1,006,093,316,943 | KRW |
| 부채총계 | 712,772,241,623 | 822,117,616,379 | 858,029,763,618 | 1,049,992,505,369 | 1,228,143,539,378 | KRW |
| 부채비율(자체 계산: 부채총계 ÷ 자본총계 × 100, 자본 0 이하면 비움, 같은 해 같은 기준)· in house | 124.27 | 135.21 | 111.82 | 132.15 | 122.07 | % |
| Statement basis | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated |
Source: dart_fnltt · Computed in house · card as of 2026-10-13 · Filing date per year: not on the card (see the filing timeline below) · 'in house' marks items computed from the values above
② Profitability breakdown
Arithmetic on the fact table only · same year, same basis · '—' where a value is missing or the denominator is 0 or below · in each panel the bar height maps the span from the most negative to the largest positive value onto the panel height · no interpretation attached
Source: computed in house from the fact table · card as of 2026-10-13
③ My own calculation
A simple residual-income formula. You enter the assumptions; only the base equity is filled in from the filing. The result is computed from your assumptions and is not a figure this site publishes.
V = B₀ + (ROE − r) × B₀ ÷ (1 + r − ω)
Fill in all four boxes to compute. The site fills in nothing but the base equity.
Computed in this browser only; nothing you type is sent or stored.
- Base close 2026-10-13
- 107,300
- 80%
- 103,272.72 ~ 112,386.08
- 90%
- 101,813.06 ~ 114,113.23
- Ledger row
- f8cdff4b…
Source: fsc_stock_price · published 2026-10-14T11:05:08+09:00 · No direction implied
No day scored yet — no basis for a hit rate.
- 2026-09-09Filing title as filed임시주주총회결과 original ↗Source: dart_disclosure
- 2026-09-09Filing title as filed독립이사의선임ㆍ해임또는중도퇴임에관한신고 original ↗Source: dart_disclosure
- 2026-09-04Filing title as filed타인에대한채무보증결정 original ↗Source: dart_disclosure
- 2026-09-02Filing title as filed소송등의제기ㆍ신청(일정금액이상의청구) original ↗Source: dart_disclosure
- 2026-08-25Filing title as filed의결권대리행사권유참고서류 original ↗Source: dart_disclosure
- 2026-08-25Filing title as filed주주총회소집공고 original ↗Source: dart_disclosure
- 2026-08-21Filing title as filed임원ㆍ주요주주특정증권등소유상황보고서 original ↗Source: dart_disclosure
- 2026-08-14Filing title as filed반기보고서 (2026.06) original ↗Source: dart_disclosure
- 2026-07-29Filing title as filed영업(잠정)실적(공정공시) original ↗Source: dart_disclosure
- 2026-07-28Filing title as filed주주총회소집결의 original ↗Source: dart_disclosure
- 2026-07-28Filing title as filed주주명부폐쇄기간또는기준일설정 original ↗Source: dart_disclosure
- 2026-07-10Filing title as filed투자판단관련주요경영사항 (펙수클루정(Fexuclue)의 적응증 추가 국내 3상 임상시험계획(IND) 승인(미란성 위식도역류질환 치료 후 유지요법)) original ↗Source: dart_disclosure
- 2026-07-07Filing title as filed임원ㆍ주요주주특정증권등소유상황보고서 original ↗Source: dart_disclosure
- 2026-06-30Filing title as filed[기재정정]신규시설투자등 original ↗Source: dart_disclosure
- 2026-06-30Filing title as filed지속가능경영보고서등관련사항(자율공시) original ↗Source: dart_disclosure
- 2026-06-26Filing title as filed단일판매ㆍ공급계약체결 original ↗Source: dart_disclosure
- 2026-06-23Filing title as filed투자판단관련주요경영사항 (펙수클루정(Fexuclue)의 적응증 추가 3상 임상시험계획(IND) 승인(위궤양의 치료 요법)) original ↗Source: dart_disclosure
- 2026-06-01Filing title as filed기업지배구조보고서공시 original ↗Source: dart_disclosure
- 2026-05-26Filing title as filed투자판단관련주요경영사항 (엔블로젬(Envlozem)의 국내 품목허가 신청) original ↗Source: dart_disclosure
- 2026-05-26Filing title as filed투자판단관련주요경영사항 (엔블로정(Envlo) 0.3mg 멕시코 품목허가 승인) original ↗Source: dart_disclosure
| Layer | Badge | n | Note |
|---|---|---|---|
| range | unknown | 0 | 80%·90% 범위의 전향 적중 기록(목표일 개장 전 박제 → 종가 공표 뒤 채점) |
| fair_value | 제공 안 함 | 0 | 판별력 미확인 — 싣지 않음 |
| direction | 제공 안 함 | 0 | 판별력 미확인 — 싣지 않음 |
| trade_levels | 제공 안 함 | 0 | 판별력 미확인 — 싣지 않음 |
| Valuation estimate | not provided | — | Not published: no demonstrated discriminative power |
| Direction (up or down) | not provided | — | Not published: no demonstrated discriminative power |
| Trading levels | not provided | — | Not published: no demonstrated discriminative power |
Why this?
Checking…